TABLE 2.
Rationale for Antifungal Prescription Grouped by Underlying Condition
| Underlying condition,* N (%) | Prophylaxis, n = 419 | Treatment, n = 237 | P value | Total, n = 656 |
|---|---|---|---|---|
| Malignancy | 230 (54.8) | 134 (56.5) | 0.664 | 364 (55.5) |
| Leukemia | 173 (75.2) | 80 (59.8) | 253 (71.4) | |
| Lymphoma | 15 (6.5) | 11 (8.3) | 26 (7.3) | |
| Solid organ tumor | 38 (16.5) | 42 (31.2) | 80 (22.6) | |
| Other | 4 (1.8) | 1 (0.7) | 5 (1.4) | |
| HSCT recipients† | 145 (34.7) | 33 (13.9) | <0.01 | 178 (27.1) |
| Primary Immunodeficiency | 55 (13.2) | 15 (6.3) | <0.01 | 70 (10.7) |
| Others | 126 (30.1) | 81 (34.2) | 0.286 | 207 (31.6) |
*No underlying condition reported in 15 patients.
†Irrespective of underlying condition.